ASCO GI 2023 Conference Coverage


 

ASCO GI 2023 Randomized Phase II VELO Clinical Trial: Panitumumab + Trifluridine/Tipiracil as Anti-EGFR Rechallenge Therapy in Chemo-Refractory RAS WT mCRC

146 views
February 16, 2023
Comments 0
Login to view comments. Click here to Login